Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Rohit Dhall

TitleAssociate Professor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentNeurology, College of Medicine
DivisionNeurology Faculty
Address501 Jack Stephens Drive
Mail Slot # 500
Little Rock AR 72205
Phone501-686-7236
ORCID ORCID Icon0000-0001-9436-1920 Additional info
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    I am a neurologist with expertise in diagnosis and management of movement disorders, including parkinsonism, dystonia and tremor. My research interests focus on development of novel diagnostics and therapeutics for neurological disorders, often through large multicenter clinical trials. I am also interested in developing and improving programs delivering care to neurological patients.


    Collapse Biography 
    Collapse Leadership and Administrative Roles
    Director of Neurodegenerative Disorders

    Medical Director, Clinical Trials Innovation Unit

    Collapse education and training
    All India Institute of Medical Sciences, IndiaMBBS (MD)12/2000Medicine, Surgery
    Univ. of Texas at Houston, School of Public Health, Houston, TXMSPH12/2008Epidemiology
    Univ. of Alabama at Birmingham, Birmingham, AKResidency training07/2007Neurology
    Univ. of Alabama at Birmingham, Birmingham, ALFellowship Training07/2009Movement Disorders and Deep Brain Stimulation
    American Association of Physician LeadersCertified Physician Executive11/2019Physician Leadership

    Collapse Research Funds 
    Collapse research activities
    M15-736     (DHALL, ROHIT)Sep 18, 2020
    AbbVie Inc
    A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson's Disease Patients (260684)
    Role: Principal Investigator

    ALXN1210-MG-306     (DHALL, ROHIT)Sep 9, 2020
    Alexion Pharmaceuticals - Pass Through: Syneos Health
    A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naive Adult Patients With Generalized Myasthenia Gravis (261071)
    Role: Principal Investigator

    NLY01-PD-1,     (DHALL, ROHIT)Jun 11, 2020
    Neuraly - Pass Through: Rho, Inc
    Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of 36 Weeks of Treatment with NLY01 in Early-Stage Parkinson's Disease (260593)
    Role: Principal Investigator

    IPX203-B16-03     (DHALL, ROHIT)Dec 9, 2019
    Syneos Health
    AN OPEN-LABEL EXTENSION STUDY OF THE SAFETY AND CLINICAL UTILITY OF IPX203 IN PARKINSON’S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS (IRB 239627)
    Role: Principal Investigator

    Study 003     (DHALL, ROHIT)Oct 25, 2019 - Oct 29, 2024
    Global Kinetics Corporation Ltd.
    Utilization of Target Ranges to Treat Patients with Parkinson’s Disease by Objective Measurement Using the Personal KinetiGraph® (PKG®) compared to Standard of Care Assessment (TARGET-PD)- A Randomized Controlled Trial (IRB 250009)
    Role: Principal Investigator

    IPX203-B16-02     (DHALL, ROHIT)May 15, 2019
    Impax Laboratories, Inc.
    A RANDOMIZED CONTROLLED STUDY TO COMPARE THE SAFETY AND EFFICACY OF IPX203 WITH IMMEDIATE-RELEASE CARBIDOPA-LEVODOPA IN PARKINSON’S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS (228747)
    Role: Principal Investigator

    IRB # 228403     (DHALL, ROHIT)Jan 8, 2019
    Cala Health, Inc
    PROSPECT: Prospective Study for Symptomatic Relief of ET with Cala Therapy (IRB 228403)
    Role: Principal Investigator

    P2B001-003     (DHALL, ROHIT)Aug 16, 2018
    Pharma Two B - Pass Through: Pharmaceutical Research Associates, Inc.
    Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to its Individual Components in Subjects With Early Parkinson’s Disease and to a Calibration Arm of Pramipexole ER.
    Role: Principal Investigator

    TOZ-CL06     (DHALL, ROHIT)Aug 8, 2017
    Biotie Therapies Inc.
    A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa- Treated Patients with Parkinson’s Disease Experiencing End of Dose “Wearing-Off”
    Role: Principal Investigator

    RVT-102-2003     (DHALL, ROHIT)Jul 28, 2017
    Axovant Sciences, Ltd.
    An open-label study of nelotanserin in patients with Lewy body dementia who have frequent visual hallucinations or REM sleep behaviors
    Role: Principal Investigator

    RVT-102-2002     (DHALL, ROHIT)May 17, 2017
    Axovant Sciences, Ltd.
    a Phase 2, double-blind, randomized, placebo-controlled study of nelotanserin versus placebo in patients with dementia with Lewy bodies (DLB) and Parkingson's Disease Dementia (PDD) who have REM Sleep behavior disorder (RBD)
    Role: Principal Investigator

    IPX203-B16-01     (DHALL, ROHIT)Mar 29, 2017
    Impax Laboratories, Inc.
    A Randomized, Multiple Dose Study to Assess the Pharmacokinetics and Pharmacodynamics of IPX203 in Subjects with Advanced Parkinson’s Disease 205998
    Role: Principal Investigator

    Collapse Outreach 

    Collapse Bibliographic 
    Collapse additional bibliographic sources
    The links below are provided by the researcher to provide access to external online bibliographies that they keep independently from the Profiles System.
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Isaacson SH, Peckham E, Tse W, Waln O, Way C, Petrossian MT, Dahodwala N, Soileau MJ, Lew M, Dietiker C, Luthra N, Agarwal P, Dhall R, Morgan J, Calakos N, Zesiewicz TA, Shamim EA, Kumar R, LeWitt P, Shill HA, Simmons A, Pagan FL, Khemani P, Tate J, Maddux B, Luo L, Ondo W, Hallett M, Rajagopal A, Chidester P, Rosenbluth KH, Delp SL, Pahwa R. Prospective Home-use Study on Non-invasive Neuromodulation Therapy for Essential Tremor. Tremor Other Hyperkinet Mov (N Y). 2020 Aug 14; 10:29. PMID: 32864188.
      View in: PubMed
    2. Grosset DG, Dhall R, Gurevich T, Kassubek J, Poewe WH, Rascol O, Rudzinska M, Cormier J, Sedkov A, Oh C. Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study. Parkinsonism Relat Disord. 2020 02; 71:4-10. PMID: 31927343.
      View in: PubMed
    3. Mirzadeh Z, Chen T, Chapple KM, Lambert M, Karis JP, Dhall R, Ponce FA. Procedural Variables Influencing Stereotactic Accuracy and Efficiency in Deep Brain Stimulation Surgery. Oper Neurosurg (Hagerstown). 2019 07 01; 17(1):70-78. PMID: 30339204.
      View in: PubMed
    4. Pahwa R, Dhall R, Ostrem J, Gwinn R, Lyons K, Ro S, Dietiker C, Luthra N, Chidester P, Hamner S, Ross E, Delp S. An Acute Randomized Controlled Trial of Noninvasive Peripheral Nerve Stimulation in Essential Tremor. Neuromodulation. 2019 Jul; 22(5):537-545. PMID: 30701655.
      View in: PubMed
    5. Santiago A, Langston JW, Gandhy R, Dhall R, Brillman S, Rees L, Barlow C. Qualitative Evaluation of the Personal KinetiGraphTM Movement Recording System in a Parkinson's Clinic. J Parkinsons Dis. 2019; 9(1):207-219. PMID: 30412506.
      View in: PubMed
    6. Morgan JC, Dhall R, Rubens R, Khanna S, Gupta S. Dosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson's Disease with Motor Fluctuations. Parkinsons Dis. 2018; 2018:9763057. PMID: 30425824.
      View in: PubMed
    7. Chen T, Mirzadeh Z, Chapple KM, Lambert M, Shill HA, Moguel-Cobos G, Tröster AI, Dhall R, Ponce FA. Clinical outcomes following awake and asleep deep brain stimulation for Parkinson disease. J Neurosurg. 2018 03 16; 130(1):109-120. PMID: 29547091.
      View in: PubMed
    8. Lieberman A, Deep A, Shi J, Dhall R, Shafer S, Moguel-Cobos G, Dhillon R, Frames CW, McCauley M. Downward finger displacement distinguishes Parkinson disease dementia from Alzheimer disease. Int J Neurosci. 2018 Feb; 128(2):151-154. PMID: 28911255.
      View in: PubMed
    9. Leehey M, Luo S, Sharma S, Wills AA, Bainbridge JL, Wong PS, Simon DK, Schneider J, Zhang Y, Pérez A, Dhall R, Christine CW, Singer C, Cambi F, Boyd JT. Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores. Neurology. 2017 Oct 24; 89(17):1789-1794. PMID: 28972194.
      View in: PubMed
    10. Beck CA, Beran DB, Biglan KM, Boyd CM, Dorsey ER, Schmidt PN, Simone R, Willis AW, Galifianakis NB, Katz M, Tanner CM, Dodenhoff K, Aldred J, Carter J, Fraser A, Jimenez-Shahed J, Hunter C, Spindler M, Reichwein S, Mari Z, Dunlop B, Morgan JC, McLane D, Hickey P, Gauger L, Richard IH, Mejia NI, Bwala G, Nance M, Shih LC, Singer C, Vargas-Parra S, Zadikoff C, Okon N, Feigin A, Ayan J, Vaughan C, Pahwa R, Dhall R, Hassan A, DeMello S, Riggare SS, Wicks P, Achey MA, Elson MJ, Goldenthal S, Keenan HT, Korn R, Schwarz H, Sharma S, Stevenson EA, Zhu W. National randomized controlled trial of virtual house calls for Parkinson disease. Neurology. 2017 Sep 12; 89(11):1152-1161. PMID: 28814455.
      View in: PubMed
    11. Ho AL, Ali R, Connolly ID, Henderson JM, Dhall R, Stein SC, Halpern CH. Awake versus asleep deep brain stimulation for Parkinson's disease: a critical comparison and meta-analysis. J Neurol Neurosurg Psychiatry. 2018 07; 89(7):687-691. PMID: 28250028.
      View in: PubMed
    12. Espay AJ, Pagan FL, Walter BL, Morgan JC, Elmer LW, Waters CH, Agarwal P, Dhall R, Ondo WG, Klos KJ, Silver DE. Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy. Neurol Clin Pract. 2017 Feb; 7(1):86-93. PMID: 28243505.
      View in: PubMed
    13. Hauser RA, Li R, Pérez A, Ren X, Weintraub D, Elm J, Goudreau JL, Morgan JC, Fang JY, Aminoff MJ, Christine CW, Dhall R, Umeh CC, Boyd JT, Stover N, Leehey M, Zweig RM, Nicholas AP, Bodis-Wollner I, Willis A, Kieburtz K, Tilley BC. Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1. J Parkinsons Dis. 2017; 7(1):117-127. PMID: 27911341.
      View in: PubMed
    14. Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, Kinel S, Leavitt B, Oakes D, O'Neill C, Vaughan C, Goldstein J, Herzog M, Snively V, Whaley J, Wong C, Suter G, Jankovic J, Jimenez-Shahed J, Hunter C, Claassen DO, Roman OC, Sung V, Smith J, Janicki S, Clouse R, Saint-Hilaire M, Hohler A, Turpin D, James RC, Rodriguez R, Rizer K, Anderson KE, Heller H, Carlson A, Criswell S, Racette BA, Revilla FJ, Nucifora F, Margolis RL, Ong M, Mendis T, Mendis N, Singer C, Quesada M, Paulsen JS, Brashers-Krug T, Miller A, Kerr J, Dubinsky RM, Gray C, Factor SA, Sperin E, Molho E, Eglow M, Evans S, Kumar R, Reeves C, Samii A, Chouinard S, Beland M, Scott BL, Hickey PT, Esmail S, Fung WL, Gibbons C, Qi L, Colcher A, Hackmyer C, McGarry A, Klos K, Gudesblatt M, Fafard L, Graffitti L, Schneider DP, Dhall R, Wojcieszek JM, LaFaver K, Duker A, Neefus E, Wilson-Perez H, Shprecher D, Wall P, Blindauer KA, Wheeler L, Boyd JT, Houston E, Farbman ES, Agarwal P, Eberly SW, Watts A, Tariot PN, Feigin A, Evans S, Beck C, Orme C, Edicola J, Christopher E. Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. JAMA. 2016 Jul 05; 316(1):40-50. PMID: 27380342.
      View in: PubMed
    15. Dhall R, Kreitzman DL. Advances in levodopa therapy for Parkinson disease: Review of RYTARY (carbidopa and levodopa) clinical efficacy and safety. Neurology. 2016 Apr 05; 86(14 Suppl 1):S13-24. PMID: 27044646.
      View in: PubMed
    16. Dorsey ER, Achey MA, Beck CA, Beran DB, Biglan KM, Boyd CM, Schmidt PN, Simone R, Willis AW, Galifianakis NB, Katz M, Tanner CM, Dodenhoff K, Ziman N, Aldred J, Carter J, Jimenez-Shahed J, Hunter C, Spindler M, Mari Z, Morgan JC, McLane D, Hickey P, Gauger L, Richard IH, Bull MT, Mejia NI, Bwala G, Nance M, Shih L, Anderson L, Singer C, Zadikoff C, Okon N, Feigin A, Ayan J, Vaughan C, Pahwa R, Cooper J, Webb S, Dhall R, Hassan A, Weis D, DeMello S, Riggare SS, Wicks P, Smith J, Keenan HT, Korn R, Schwarz H, Sharma S, Stevenson EA, Zhu W. National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers. Telemed J E Health. 2016 07; 22(7):590-8. PMID: 26886406.
      View in: PubMed
    17. Chen T, Mirzadeh Z, Chapple K, Lambert M, Dhall R, Ponce FA. "Asleep" deep brain stimulation for essential tremor. J Neurosurg. 2016 Jun; 124(6):1842-9. PMID: 26613177.
      View in: PubMed
    18. Mirzadeh Z, Chapple K, Lambert M, Evidente VG, Mahant P, Ospina MC, Samanta J, Moguel-Cobos G, Salins N, Lieberman A, Tröster AI, Dhall R, Ponce FA. Parkinson's disease outcomes after intraoperative CT-guided "asleep" deep brain stimulation in the globus pallidus internus. J Neurosurg. 2016 Apr; 124(4):902-7. PMID: 26452116.
      View in: PubMed
    19. Augustine EF, Pérez A, Dhall R, Umeh CC, Videnovic A, Cambi F, Wills AM, Elm JJ, Zweig RM, Shulman LM, Nance MA, Bainbridge J, Suchowersky O. Sex Differences in Clinical Features of Early, Treated Parkinson's Disease. PLoS One. 2015; 10(7):e0133002. PMID: 26171861.
      View in: PubMed
    20. Bega D, Luo S, Fernandez H, Chou K, Aminoff M, Parashos S, Walker H, Russell DS, Christine CW, Dhall R, Singer C, Bodis-Wollner I, Hamill R, Truong D, Mari Z, Glazmann S, Huang M, Houston E, Simuni T. Impact of Depression on Progression of Impairment and Disability in Early Parkinson's Disease. Mov Disord Clin Pract. 2015 Dec; 2(4):371-378. PMID: 28393083.
      View in: PubMed
    21. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol. 2015 Aug; 14(8):795-803. PMID: 26116315.
      View in: PubMed
    22. Pan D, Dhall R, Lieberman A, Petitti DB. A mobile cloud-based Parkinson's disease assessment system for home-based monitoring. JMIR Mhealth Uhealth. 2015 Mar 26; 3(1):e29. PMID: 25830687.
      View in: PubMed
    23. Lieberman A, Deep A, Dhall R, Tran A, Liu MJ. Early Freezing of Gait: Atypical versus Typical Parkinson Disorders. Parkinsons Dis. 2015; 2015:951645. PMID: 25785228.
      View in: PubMed
    24. Fang JY, Pérez A, Christine CW, Leehey M, Aminoff MJ, Boyd JT, Morgan JC, Dhall R, Nicholas AP, Bodis-Wollner I, Zweig RM, Goudreau JL. Parkinson's disease severity and use of dopaminergic medications. Parkinsonism Relat Disord. 2015 Mar; 21(3):297-9. PMID: 25541182.
      View in: PubMed
    25. Umeh CC, Pérez A, Augustine EF, Dhall R, Dewey RB, Mari Z, Simon DK, Wills AM, Christine CW, Schneider JS, Suchowersky O. No sex differences in use of dopaminergic medication in early Parkinson disease in the US and Canada - baseline findings of a multicenter trial. PLoS One. 2014; 9(12):e112287. PMID: 25486269.
      View in: PubMed
    26. Mirzadeh Z, Chapple K, Lambert M, Dhall R, Ponce FA. Validation of CT-MRI fusion for intraoperative assessment of stereotactic accuracy in DBS surgery. Mov Disord. 2014 Dec; 29(14):1788-95. PMID: 25377213.
      View in: PubMed
    27. Lieberman A, Dhall R, Salins N, Sadreddin A, Moguel-Cobos G, Karis J, Krishnamurthi N. Finger displacement in Parkinson disease: up? down? sideways? Int J Neurosci. 2014 May; 124(5):339-43. PMID: 24053160.
      View in: PubMed
    28. Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014 Feb 08; 383(9916):533-40. PMID: 24183563.
      View in: PubMed
    29. Lieberman A, Dhall R, Dhanani S, Salins N, Sadreddin A, Moguel-Cobos G, Pan D, Santiago A, Prigatano G, Krishnamurthi N, Troster A. Distinguishing the tremor of Parkinson's disease from essential tremor: finger displacement. Int J Neurosci. 2014 Mar; 124(3):175-80. PMID: 23879402.
      View in: PubMed
    30. Elm JJ. Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov Disord. 2012 Oct; 27(12):1513-21. PMID: 23079770.
      View in: PubMed
    31. Lieberman A, Krishnamurthi N, Dhall R, Santiago A, Moguel-Cobos G, Sadreddin A, Husain S, Salins N, Pan D. A simple question about falls to distinguish balance and gait difficulties in Parkinson's disease. Int J Neurosci. 2012 Dec; 122(12):710-5. PMID: 22784291.
      View in: PubMed
    32. Oh SJ, Dhall R, Young A, Morgan MB, Lu L, Claussen GC. Statins may aggravate myasthenia gravis. Muscle Nerve. 2008 Sep; 38(3):1101-7. PMID: 18720508.
      View in: PubMed
    Dhall's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _